Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment
Authors:
- 1 June 1981
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 1 (2) , 91-95
Abstract
Fifty-three women with actively progressing advanced breast cancer, who had all previously received tamoxifen, were treated with aminoglutethimide to induce medical adrenalectomy. Sixty-nine percent of the patients who had previously responded to tamoxifen subsequently responded to aminoglutethimide, while thirty-five percent of the nonresponders to tamoxifen subsequently responded to aminoglutethimide. The median duration of remission to aminoglutethimide was 12 months with a range from 4 to 22 + months. The drug was well tolerated and would appear to be the treatment of choice in tamoxifen responsive cases of advanced breast cancer.Keywords
This publication has 10 references indexed in Scilit:
- MEDICAL ADRENALECTOMY WITH AMINOGLUTETHIMIDE IN THE MANAGEMENT OF ADVANCED BREAST CANCERMedical Journal of Australia, 1981
- Cancer of the BreastNew England Journal of Medicine, 1980
- TAMOXIFEN-INDUCED TUMOR-STIMULATION AND WITHDRAWAL RESPONSE1979
- The use of steroïd hormone receptors in the treatment of human breast cancer: a review.1979
- Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*The Journal of Clinical Endocrinology & Metabolism, 1978
- AMINOGLUTETHIMIDE IN TREATMENT OF METASTATIC BREAST CARCINOMAThe Lancet, 1978
- Medical Adrenalectomy with AminoglutethimideAnnals of Surgery, 1978
- Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, SwitzerlandCancer, 1977
- Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptorEuropean Journal of Cancer (1965), 1975
- Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancerCancer, 1974